相关实验视频

Updated: May 29, 2025

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

A Model for Encephalomyosynangiosis Treatment after Middle Cerebral Artery Occlusion-Induced Stroke in Mice

Published on: June 22, 2022

MT2A通过铜-线粒体调节机制促进慢性缺血大脑中的血管生成

Ni Mo¹, Chuyang Tai¹, Yang Yang²

¹Department of Neurosurgery, Third Affiliated Hospital of Sun Yat-Sen University, No. 600 Tianhe Road, Guangzhou, Guangdong Province, PR China.

Journal of translational medicine

|February 6, 2025

概括

金属氨酸2A (MT2A) 通过中和有毒的铜离子并改善线粒体功能,促进慢性缺血性脑血管疾病中的血管生成. 这项研究研究了MT2A.

科学领域:

神经科学是一个神经科学.
血管生物学血管生物学
线粒体医学线粒体医学

背景情况:

慢性缺血性脑血管疾病 (CICD) 影响大约50%的患者的重血管化.
金属氨酸2A (MT2A) 结合金属离子,可以减轻铜诱导的血管生成损伤.
铜过载 (CPO) 假设会损害CICD中的血管生成,MT2A可能提供治疗效益.

研究的目的:

研究MT2A在在铜过载 (CPO) 条件下促进慢性缺血大脑血管生成中的作用.
阐明MT2A对抗CPO诱导的线粒体功能障碍和细胞毒性的机制.
评估MT2A在CPO慢性脑缺血的老鼠模型中的治疗潜力.

主要方法:

在CICD患者的硬质体中分析与cuproptosis相关的基因表达 (DLAT,FDX1,SDHB).
使用人静脉内皮细胞 (HUVECs) 暴露在化铜 (CuCl2) 和elaclomol中以诱导CPO的体外研究,评估细胞活力,线粒体结构和功能.
使用CPO建立2血管封闭加上脑神经同流症 (2VO+EMS) 的老鼠模型,以评估MT2A在体内产生的益血管效应.

主要成果:

较差再血管化的CICD患者表现出与cuproptosis相关的基因的改变表达.
在实验室中,CPO损害了HUVEC活性和线粒体功能,由DLAT寡合化和减少SDHB表达而证明.
在体外和体内,MT2A的过度表达显著缓解了CPO诱导的线粒体功能障碍,细胞毒性,并抑制了脑血管生成,同时改善了大脑血液输液和大鼠的认知功能.

结论:

MT2A在促进慢性缺血大脑中的血管生成方面发挥着至关重要的作用.
MT2A有效中和过多的铜离子,从而减轻CPO诱导的线粒体功能障碍.
在CICD中,MT2A显示了改善重血管化和认知功能的治疗潜力.

关键词:

血管新生的产生.慢性缺血性脑血管疾病是什么铜过载是因为铜过载.这种疾病叫做cuproptosis.内皮细胞内皮细胞的内皮细胞.在2A中的金属氨酸.线粒体中的线粒体.

更多相关视频

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

A Modified Surgical Model of Hind Limb Ischemia in ApoE-/- Mice using a Miniature Incision

A Modified Surgical Model of Hind Limb Ischemia in ApoE-/- Mice using a Miniature Incision

Published on: May 13, 2021

相关概念视频

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

Mechanism of Angiogenesis

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...